Engineering and screening the N-terminus of chemokines for drug discovery

Biochemical Pharmacology

Volumn 82, Issue 10, 2011, Pages 1438-1456

  Chevigné, Andy ^a   Fievez, Virginie ^a   Schmit, Jean Claude ^a,b   Deroo, Sabrina ^a  

^a Retrovirology Laboratory Luxembourg   (Luxembourg)

^b CENTRE HOSPITALIER DE LUXEMBOURG   (Luxembourg)

Author keywords

Antagonists; CCR5; Chemokine analogues; Chemokine receptors; CXCR4; Therapeutic peptides

Indexed keywords

CHEMOKINE; CXCL12A CHEMOKINE; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; PEPTIDE; RANTES; UNCLASSIFIED DRUG; CCL11 CHEMOKINE[2-74]; CCL14 CHEMOKINE[10-74]; CCL2 CHEMOKINE[1-10]; CCL2 CHEMOKINE[1-11]; CCL2 CHEMOKINE[1-21]; CCL2 CHEMOKINE[6-18]; CCL2 CHEMOKINE[9-76]; CCL5 CHEMOKINE[1-10]; CCL5 CHEMOKINE[2-14]; CCL5 CHEMOKINE[3-12]; CCL5 CHEMOKINE[5-14]; CCL5 CHEMOKINE[6-14]; CCL5 CHEMOKINE[7-14]; CCL5 CHEMOKINE[8-14]; CCL5 CHEMOKINE[8-68]; CCL5 CHEMOKINE[9-68]; CCL7 CHEMOKINE[10-76]; CHEMOKINE RECEPTOR; CXCL12A CHEMOKINE[1-13]; CXCL12A CHEMOKINE[1-17]; CXCL12A CHEMOKINE[1-8]; CXCL12A CHEMOKINE[1-9]; CXCL12A CHEMOKINE[2-67]; CXCL12A CHEMOKINE[3-14]; CXCL12A CHEMOKINE[3-67]; CXCL12A CHEMOKINE[5-14]; CXCL12A CHEMOKINE[5-16]; CXCL12A CHEMOKINE[9-67]; UNINDEXED DRUG;

AMINO TERMINAL SEQUENCE; CONFERENCE PAPER; DRUG DEVELOPMENT; INFLAMMATION; MUTAGENESIS; NONHUMAN; PHARMACOPHORE; PRIORITY JOURNAL; RECEPTOR AFFINITY; ALLERGY; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; BETA SHEET; BETA TURN; BINDING AFFINITY; BIOMEDICAL ENGINEERING; CARDIOMYOPATHY; CHEMICAL MODIFICATION; DRUG SCREENING; ENTERITIS; GENE MUTATION; GRAFT REJECTION; HEPATITIS; HERPES SIMPLEX; HUMAN; PANCREATITIS; PEPTIDE LIBRARY; PEPTIDE MAPPING; PERIODONTITIS; PROTEIN FOLDING; RECEPTOR BINDING; RESPIRATORY TRACT INFLAMMATION; TUMOR GROWTH;

CHEMOKINES; DRUG DISCOVERY; GENE EXPRESSION REGULATION; MODELS, MOLECULAR; PROTEIN CONFORMATION; PROTEIN ENGINEERING;

EID: 80054702301     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2011.07.091     Document Type: Conference Paper

References (218)

1. T. Yoshimura, K. Matsushima, J.J. Oppenheim, and E.J. Leonard Neutrophil chemotactic factor produced by lipopolysaccharide (LPS)-stimulated human blood mononuclear leukocytes: partial characterization and separation from interleukin 1 (IL 1) J Immunol 139 1987 788 793 (Pubitemid 17107077)
2. T. Yoshimura, K. Matsushima, S. Tanaka, E.A. Robinson, E. Appella, and J.J. Oppenheim Purification of a human monocyte-derived neutrophil chemotactic factor that has peptide sequence similarity to other host defense cytokines Proc Natl Acad Sci USA 84 1987 9233 9237
3. K. Matsushima, C.G. Larsen, G.C. DuBois, and J.J. Oppenheim Purification and characterization of a novel monocyte chemotactic and activating factor produced by a human myelomonocytic cell line J Exp Med 169 1989 1485 1490 (Pubitemid 19104979)
4. B. Moser, M. Wolf, A. Walz, and P. Loetscher Chemokines: multiple levels of leukocyte migration control Trends Immunol 25 2004 75 84 (Pubitemid 38167488)
5. I. Clark-Lewis, K.S. Kim, K. Rajarathnam, J.H. Gong, B. Dewald, and B. Moser Structure-activity relationships of chemokines J Leukoc Biol 57 1995 703 711
6. A. Zlotnik, and O. Yoshie Chemokines: a new classification system and their role in immunity Immunity 12 2000 121 127 (Pubitemid 30398626)
7. M. Baggiolini, B. Dewald, and B. Moser Interleukin-8 and related chemotactic cytokines - CXC and CC chemokines Adv Immunol 55 1994 97 179
8. M.B. Furie, and G.J. Randolph Chemokines and tissue injury Am J Pathol 146 1995 1287 1301
9. D. Rossi, and A. Zlotnik The biology of chemokines and their receptors Annu Rev Immunol 18 2000 217 242
10. P.M. Murphy The molecular biology of leukocyte chemoattractant receptors Annu Rev Immunol 12 1994 593 633 (Pubitemid 24140426)
11. A.C. Hanyaloglu, and M. von Zastrow Regulation of GPCRs by endocytic membrane trafficking and its potential implications Annu Rev Pharmacol Toxicol 48 2008 537 568 (Pubitemid 351738163)
12. E. Kelly, C.P. Bailey, and G. Henderson Agonist-selective mechanisms of GPCR desensitization Br J Pharmacol 153 Suppl. 1 2008 S379 S388
13. A. Marchese, M.M. Paing, B.R. Temple, and J. Trejo G protein-coupled receptor sorting to endosomes and lysosomes Annu Rev Pharmacol Toxicol 48 2008 601 629 (Pubitemid 351738165)
14. M.P. Crump, J.H. Gong, P. Loetscher, K. Rajarathnam, A. Amara, and F. Arenzana-Seisdedos Solution structure and basis for functional activity of stromal cell-derived factor-1; dissociation of CXCR4 activation from binding and inhibition of HIV-1 EMBO J 16 1997 6996 7007 (Pubitemid 27520800)
15. X. Huang, J. Shen, M. Cui, L. Shen, X. Luo, and K. Ling Molecular dynamics simulations on SDF-1alpha: binding with CXCR4 receptor Biophys J 84 2003 171 184 (Pubitemid 36026388)
16. Y. Kofuku, C. Yoshiura, T. Ueda, H. Terasawa, T. Hirai, and S. Tominaga Structural basis of the interaction between chemokine stromal cell-derived factor-1/CXCL12 and its G-protein-coupled receptor CXCR4 J Biol Chem 284 2009 35240 35250
17. F. Balkwill Chemokine biology in cancer Semin Immunol 15 2003 49 55 (Pubitemid 36092178)
18. C. Gerard, and B.J. Rollins Chemokines and disease Nat Immunol 2 2001 108 115 (Pubitemid 33707927)
19. E.A. Berger HIV. entry and tropism: the chemokine receptor connection AIDS 11 Suppl. A 1997 S3 S16
20. Y. Feng, C.C. Broder, P.E. Kennedy, and E.A. Berger HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor Science 272 1996 872 877 (Pubitemid 26154590)
21. Y. Jiang, L.A. Tabak, A.J. Valente, and D.T. Graves Initial characterization of the carbohydrate structure of MCP-1 Biochem Biophys Res Commun 178 1991 1400 1404
22. J.M. Schroder, M. Sticherling, N.L. Persoon, and E. Christophers Identification of a novel platelet-derived neutrophil-chemotactic polypeptide with structural homology to platelet-factor 4 Biochem Biophys Res Commun 172 1990 898 904 (Pubitemid 20384508)
23. T. Yoshimura, E.A. Robinson, E. Appella, K. Matsushima, S.D. Showalter, and A. Skeel Three forms of monocyte-derived neutrophil chemotactic factor (MDNCF) distinguished by different lengths of the amino-terminal sequence Mol Immunol 26 1989 87 93 (Pubitemid 19024646)
24. C. Capoulade-Metay, A. Ayouba, A. Kfutwah, K. Lole, S. Petres, and Y. Dudoit A natural CCL5/RANTES variant antagonist for CCR1 and CCR3 Immunogenetics 58 2006 533 541 (Pubitemid 44025528)
25. A. Mortier, J. Van Damme, and P. Proost Regulation of chemokine activity by posttranslational modification Pharmacol Ther 120 2008 197 217
26. A. Mortier, M. Gouwy, J. Van Damme, and P. Proost Effect of posttranslational processing on the in vitro and in vivo activity of chemokines Exp Cell Res 317 2011 642 654
27. C.A. Hebert, R.V. Vitangcol, and J.B. Baker Scanning mutagenesis of interleukin-8 identifies a cluster of residues required for receptor binding J Biol Chem 266 1991 18989 18994 (Pubitemid 21908180)
28. 2-terminal residues and evidence for uncoupling of neutrophil chemotaxis, exocytosis, and receptor binding activities J Biol Chem 266 1991 23128 23134 (Pubitemid 21908769)
29. H.B. Lowman, P.H. Slagle, L.E. DeForge, C.M. Wirth, B.L. Gillece-Castro, and J.H. Bourell Exchanging interleukin-8 and melanoma growth-stimulating activity receptor binding specificities J Biol Chem 271 1996 14344 14352 (Pubitemid 26190332)
30. B. Moser, B. Dewald, L. Barella, C. Schumacher, M. Baggiolini, and I. Clark-Lewis Interleukin-8 antagonists generated by N-terminal modification J Biol Chem 268 1993 7125 7128 (Pubitemid 23105600)
31. Z. Yan, J. Zhang, J.C. Holt, G.J. Stewart, S. Niewiarowski, and M. Poncz Structural requirements of platelet chemokines for neutrophil activation Blood 84 1994 2329 2339 (Pubitemid 24296396)
32. I. Clark-Lewis, B. Dewald, T. Geiser, B. Moser, and M. Baggiolini Platelet factor 4 binds to interleukin 8 receptors and activates neutrophils when its N terminus is modified with Glu-Leu-Arg Proc Natl Acad Sci USA 90 1993 3574 3577 (Pubitemid 23111409)
33. C.J. Beall, S. Mahajan, and P.E. Kolattukudy Conversion of monocyte chemoattractant protein-1 into a neutrophil attractant by substitution of two amino acids J Biol Chem 267 1992 3455 3459
34. S.A. Jones, B. Dewald, I. Clark-Lewis, and M. Baggiolini Chemokine antagonists that discriminate between interleukin-8 receptors. Selective blockers of CXCR2 J Biol Chem 272 1997 16166 16169 (Pubitemid 27276432)
35. S.R. McColl, and I. Clark-Lewis Inhibition of murine neutrophil recruitment in vivo by CXC chemokine receptor antagonists J Immunol 163 1999 2829 2835 (Pubitemid 29399212)
36. X. Zhao, F. Li, J.R. Town, X. Zhang, W. Wang, and J.R. Gordon Humanized forms of the CXCR1/CXCR2 antagonist, bovine CXCL8((3-74))K11R/G31P, effectively block ELR-CXC chemokine activity and airway endotoxemia pathology Int Immunopharmacol 7 2007 1723 1731 (Pubitemid 350054930)
37. J.H. Gong, and I. Clark-Lewis Antagonists of monocyte chemoattractant protein 1 identified by modification of functionally critical NH2-terminal residues J Exp Med 181 1995 631 640
38. J.H. Gong, M. Uguccioni, B. Dewald, M. Baggiolini, I. Clark-Lewis, and RANTES MCP-3 antagonists bind multiple chemokine receptors J Biol Chem 271 1996 10521 10527 (Pubitemid 26145785)
39. K. Jarnagin, D. Grunberger, M. Mulkins, B. Wong, S. Hemmerich, and C. Paavola Identification of surface residues of the monocyte chemotactic protein 1 that affect signaling through the receptor CCR2 Biochemistry 38 1999 16167 16177 (Pubitemid 129520537)
40. A. Liston, R.E. Kohler, S. Townley, S. Haylock-Jacobs, I. Comerford, and A.C. Caon Inhibition of CCR6 function reduces the severity of experimental autoimmune encephalomyelitis via effects on the priming phase of the immune response J Immunol 182 2009 3121 3130
41. A. Shinkai, M. Komuta-Kunitomo, N. Sato-Nakamura, and H. Anazawa N-terminal domain of eotaxin-3 is important for activation of CC chemokine receptor 3 Protein Eng 15 2002 923 929 (Pubitemid 36172730)
42. J.S. Laurence, C. Blanpain, J.W. Burgner, M. Parmentier, and P.J. LiWang CC chemokine MIP-1 beta can function as a monomer and depends on Phe13 for receptor binding Biochemistry 39 2000 3401 3409 (Pubitemid 30170011)
43. A. Inoue, H. Hasegawa, M. Kohno, M.R. Ito, M. Terada, and T. Imai Antagonist of fractalkine (CX3CL1) delays the initiation and ameliorates the progression of lupus nephritis in MRL/lpr mice Arthritis Rheum 52 2005 1522 1533 (Pubitemid 40663944)
44. R.J. Nibbs, T.W. Salcedo, J.D. Campbell, X.T. Yao, Y. Li, and B. Nardelli C-C chemokine receptor 3 antagonism by the beta-chemokine macrophage inflammatory protein 4, a property strongly enhanced by an amino-terminal alanine-methionine swap J Immunol 164 2000 1488 1497 (Pubitemid 30067265)
45. I. Clark-Lewis, I. Mattioli, J.H. Gong, and P. Loetscher Structure-function relationship between the human chemokine receptor CXCR3 and its ligands J Biol Chem 278 2003 289 295 (Pubitemid 36043575)
46. 2-terminal residue converts monocyte chemotactic protein 1 from an activator of basophil mediator release to an eosinophil chemoattractant J Exp Med 183 1996 681 685
47. J.H. Gong, L.G. Ratkay, J.D. Waterfield, and I. Clark-Lewis An antagonist of monocyte chemoattractant protein 1 (MCP-1) inhibits arthritis in the MRL-lpr mouse model J Exp Med 186 1997 131 137 (Pubitemid 27304855)
48. J.H. Gong, R. Yan, J.D. Waterfield, and I. Clark-Lewis Post-onset inhibition of murine arthritis using combined chemokine antagonist therapy Rheumatology (Oxford) 43 2004 39 42 (Pubitemid 38088366)
49. H. Hasegawa, M. Kohno, M. Sasaki, A. Inoue, M.R. Ito, and M. Terada Antagonist of monocyte chemoattractant protein 1 ameliorates the initiation and progression of lupus nephritis and renal vasculitis in MRL/lpr mice Arthritis Rheum 48 2003 2555 2566 (Pubitemid 37129432)
50. Y. Zhang, and B.J. Rollins A dominant negative inhibitor indicates that monocyte chemoattractant protein 1 functions as a dimer Mol Cell Biol 15 1995 4851 4855
51. Y.J. Zhang, B.J. Rutledge, and B.J. Rollins Structure/activity analysis of human monocyte chemoattractant protein-1 (MCP-1) by mutagenesis. Identification of a mutated protein that inhibits MCP-1-mediated monocyte chemotaxis J Biol Chem 269 1994 15918 15924
52. K. Egashira Molecular mechanisms mediating inflammation in vascular disease: special reference to monocyte chemoattractant protein-1 Hypertension 41 2003 834 841 (Pubitemid 36314600)
53. S. Kitamoto, and K. Egashira Gene therapy targeting monocyte chemoattractant protein-1 for vascular disease J Atheroscler Thromb 9 2002 261 265
54. L. Zhong, W.Q. Chen, X.P. Ji, M. Zhang, Y.X. Zhao, and G.H. Yao Dominant-negative mutation of monocyte chemoattractant protein-1 prevents vulnerable plaques from rupture in rabbits independent of serum lipid levels J Cell Mol Med 12 2008 2362 2371
55. K. Nakano, K. Egashira, K. Ohtani, G. Zhao, K. Funakoshi, and Y. Ihara Catheter-based adenovirus-mediated anti-monocyte chemoattractant gene therapy attenuates in-stent neointima formation in cynomolgus monkeys Atherosclerosis 194 2007 309 316 (Pubitemid 47513092)
56. K. Egashira, K. Nakano, K. Ohtani, K. Funakoshi, G. Zhao, and Y. Ihara Local delivery of anti-monocyte chemoattractant protein-1 by gene-eluting stents attenuates in-stent stenosis in rabbits and monkeys Arterioscler Thromb Vasc Biol 27 2007 2563 2568 (Pubitemid 350158906)
57. H. Tatewaki, K. Egashira, S. Kimura, T. Nishida, S. Morita, and R. Tominaga Blockade of monocyte chemoattractant protein-1 by adenoviral gene transfer inhibits experimental vein graft neointimal formation J Vasc Surg 45 2007 1236 1243 (Pubitemid 46817835)
58. Y. Kumai, H. Ooboshi, J. Takada, M. Kamouchi, T. Kitazono, and K. Egashira Anti-monocyte chemoattractant protein-1 gene therapy protects against focal brain ischemia in hypertensive rats J Cereb Blood Flow Metab 24 2004 1359 1368 (Pubitemid 40019159)
59. Y. Ikeda, Y. Yonemitsu, C. Kataoka, S. Kitamoto, T. Yamaoka, and K. Nishida Anti-monocyte chemoattractant protein-1 gene therapy attenuates pulmonary hypertension in rats Am J Physiol Heart Circ Physiol 283 2002 H2021 H2028
60. T. Kiyota, M. Yamamoto, B. Schroder, M.T. Jacobsen, R.J. Swan, and M.P. Lambert AAV1/2-mediated CNS gene delivery of dominant-negative CCL2 mutant suppresses gliosis, beta-amyloidosis, and learning impairment of APP/PS1 mice Mol Ther 17 2009 803 809
61. T. Aoki, H. Kataoka, R. Ishibashi, K. Nozaki, K. Egashira, and N. Hashimoto Impact of monocyte chemoattractant protein-1 deficiency on cerebral aneurysm formation Stroke 40 2009 942 951
62. I.K. Park, K. Hiraki, K. Kohyama, and Y. Matsumoto Differential effects of decoy chemokine (7ND) gene therapy on acute, biphasic and chronic autoimmune encephalomyelitis: implication for pathomechanisms of lesion formation J Neuroimmunol 194 2008 34 43
63. S. Goser, R. Ottl, A. Brodner, T.J. Dengler, J. Torzewski, and K. Egashira Critical role for monocyte chemoattractant protein-1 and macrophage inflammatory protein-1alpha in induction of experimental autoimmune myocarditis and effective anti-monocyte chemoattractant protein-1 gene therapy Circulation 112 2005 3400 3407 (Pubitemid 43739554)
64. M. Koga, H. Kai, K. Egami, T. Murohara, A. Ikeda, and S. Yasuoka Mutant MCP-1 therapy inhibits tumor angiogenesis and growth of malignant melanoma in mice Biochem Biophys Res Commun 365 2008 279 284 (Pubitemid 350137285)
65. H. Kanamori, T. Matsubara, A. Mima, E. Sumi, K. Nagai, and T. Takahashi Inhibition of MCP-1/CCR2 pathway ameliorates the development of diabetic nephropathy Biochem Biophys Res Commun 360 2007 772 777 (Pubitemid 47077388)
66. S. Shimizu, H. Nakashima, K. Karube, K. Ohshima, and K. Egashira Monocyte chemoattractant protein-1 activates a regional Th1 immunoresponse in nephritis of MRL/lpr mice Clin Exp Rheumatol 23 2005 239 242 (Pubitemid 40663007)
67. S. Shimizu, H. Nakashima, K. Masutani, Y. Inoue, K. Miyake, and M. Akahoshi Anti-monocyte chemoattractant protein-1 gene therapy attenuates nephritis in MRL/lpr mice Rheumatology (Oxford) 43 2004 1121 1128 (Pubitemid 39232817)
68. T. Wada, K. Furuichi, N. Sakai, Y. Iwata, K. Kitagawa, and Y. Ishida Gene therapy via blockade of monocyte chemoattractant protein-1 for renal fibrosis J Am Soc Nephrol 15 2004 940 948 (Pubitemid 38375313)
69. S. Tsuruta, M. Nakamuta, M. Enjoji, K. Kotoh, K. Hiasa, and K. Egashira Anti-monocyte chemoattractant protein-1 gene therapy prevents dimethylnitrosamine-induced hepatic fibrosis in rats Int J Mol Med 14 2004 837 842
70. S. Shahrara, A.E. Proudfoot, C.C. Park, M.V. Volin, G.K. Haines, and J.M. Woods Inhibition of monocyte chemoattractant protein-1 ameliorates rat adjuvant-induced arthritis J Immunol 180 2008 3447 3456
71. T.M. Handel, Z. Johnson, D.H. Rodrigues, A.C. Dos Santos, R. Cirillo, and V. Muzio An engineered monomer of CCL2 has anti-inflammatory properties emphasizing the importance of oligomerization for chemokine activity in vivo J Leukoc Biol 84 2008 1101 1108
72. M. Sasaki, H. Hasegawa, M. Kohno, A. Inoue, M.R. Ito, and S. Fujita Antagonist of secondary lymphoid-tissue chemokine (CCR ligand 21) prevents the development of chronic graft-versus-host disease in mice J Immunol 170 2003 588 596 (Pubitemid 36026187)
73. T.R. Ott, F.M. Lio, D. Olshefski, X.J. Liu, R.S. Struthers, and N. Ling Determinants of high-affinity binding and receptor activation in the N-terminus of CCL-19 (MIP-3 beta) Biochemistry 43 2004 3670 3678 (Pubitemid 38391721)
74. K.R. Pilkington, I. Clark-Lewis, and S.R. McColl Inhibition of generation of cytotoxic T lymphocyte activity by a CCL19/macrophage inflammatory protein (MIP)-3beta antagonist J Biol Chem 279 2004 40276 40282 (Pubitemid 39287611)
75. R.E. Kohler, I. Comerford, S. Townley, S. Haylock-Jacobs, I. Clark-Lewis, and S.R. McColl Antagonism of the chemokine receptors CXCR3 and CXCR4 reduces the pathology of experimental autoimmune encephalomyelitis Brain Pathol 18 2008 504 516
76. Y. Tan, Y. Li, J. Xiao, H. Shao, C. Ding, and G.E. Arteel A novel CXCR4 antagonist derived from human SDF-1beta enhances angiogenesis in ischaemic mice Cardiovasc Res 82 2009 513 521
77. D.R. Pakianathan, E.G. Kuta, D.R. Artis, N.J. Skelton, and C.A. Hebert Distinct but overlapping epitopes for the interaction of a CC-chemokine with CCR1, CCR3 and CCR5 Biochemistry 36 1997 9642 9648 (Pubitemid 27364674)
78. S. Fleury, J. Li, E. Simeoni, E. Fiorini, L.K. von Segesser, and L. Kappenberger Gene transfer of RANTES and MCP-1 chemokine antagonists prolongs cardiac allograft survival Gene Ther 13 2006 1104 1109
79. G. Vassalli, E. Simeoni, J.P. Li, and S. Fleury Lentiviral gene transfer of the chemokine antagonist RANTES 9-68 prolongs heart graft survival Transplantation 81 2006 240 246
80. M.D. Kelly, H.M. Naif, S.L. Adams, A.L. Cunningham, and A.R. Lloyd Dichotomous effects of beta-chemokines on HIV replication in monocytes and monocyte-derived macrophages J Immunol 160 1998 3091 3095 (Pubitemid 28164695)
81. A. Kinter, A. Catanzaro, J. Monaco, M. Ruiz, J. Justement, and S. Moir CC-chemokines enhance the replication of T-tropic strains of HIV-1 in CD4(+) T cells: role of signal transduction Proc Natl Acad Sci USA 95 1998 11880 11885 (Pubitemid 28460508)
82. F. Arenzana-Seisdedos, J.L. Virelizier, D. Rousset, I. Clark-Lewis, P. Loetscher, and B. Moser HIV blocked by chemokine antagonist Nature 383 1996 400 (Pubitemid 26330820)
83. L. Ylisastigui, J. Vizzavona, E. Drakopoulou, P. Paindavoine, C.F. Calvo, and M. Parmentier Synthetic full-length and truncated RANTES inhibit HIV-1 infection of primary macrophages AIDS 12 1998 977 984 (Pubitemid 28276964)
84. S. Polo, V. Nardese, C. De Santis, C. Arcelloni, R. Paroni, and F. Sironi Enhancement of the HIV-1 inhibitory activity of RANTES by modification of the N-terminal region: dissociation from CCR5 activation Eur J Immunol 30 2000 3190 3198
85. M. Secchi, Q. Xu, P. Lusso, and L. Vangelista The superior folding of a RANTES analogue expressed in lactobacilli as compared to mammalian cells reveals a promising system to screen new RANTES mutants Protein Expr Purif 68 2009 34 41
86. L. Vangelista, M. Secchi, X. Liu, A. Bachi, L. Jia, and Q. Xu Engineering of Lactobacillus jensenii to secrete RANTES and a CCR5 antagonist analogue as live HIV-1 blockers Antimicrob Agents Chemother 54 2010 2994 3001
87. A.E. Proudfoot, C.A. Power, A.J. Hoogewerf, M.O. Montjovent, F. Borlat, and R.E. Offord Extension of recombinant human RANTES by the retention of the initiating methionine produces a potent antagonist J Biol Chem 271 1996 2599 2603 (Pubitemid 26047869)
88. H. Olbrich, A.E. Proudfoot, and M. Oppermann Chemokine-induced phosphorylation of CC chemokine receptor 5 (CCR5) J Leukoc Biol 65 1999 281 285 (Pubitemid 29109697)
89. A.E. Proudfoot, R. Buser, F. Borlat, S. Alouani, D. Soler, and R.E. Offord Amino-terminally modified RANTES analogues demonstrate differential effects on RANTES receptors J Biol Chem 274 1999 32478 32485
90. P.A. Stumbles, D.H. Strickland, C.L. Pimm, S.F. Proksch, A.M. Marsh, and A.S. McWilliam Regulation of dendritic cell recruitment into resting and inflamed airway epithelium: use of alternative chemokine receptors as a function of inducing stimulus J Immunol 167 2001 228 234 (Pubitemid 32567782)
91. C. Plater-Zyberk, A.J. Hoogewerf, A.E. Proudfoot, C.A. Power, and T.N. Wells Effect of a CC chemokine receptor antagonist on collagen induced arthritis in DBA/1 mice Immunol Lett 57 1997 117 120 (Pubitemid 27319323)
92. S. Shahrara, A.E. Proudfoot, J.M. Woods, J.H. Ruth, M.A. Amin, and C.C. Park Amelioration of rat adjuvant-induced arthritis by Met-RANTES Arthritis Rheum 52 2005 1907 1919 (Pubitemid 40852900)
93. C. Kucuk, E. Sozuer, S. Gursoy, O. Canoz, T. Artis, and A. Akcan Treatment with Met-RANTES decreases bacterial translocation in experimental colitis Am J Surg 191 2006 77 83 (Pubitemid 43042525)
94. H.J. Grone, C. Weber, K.S. Weber, E.F. Grone, C.M. Klier, and T.N. Wells [Reduction of acute kidney transplantation rejection by the chemokine receptor antagonist Met-RANTES] Verh Dtsch Ges Pathol 83 1999 205 211
95. E. Song, H. Zou, Y. Yao, A. Proudfoot, B. Antus, and S. Liu Early application of Met-RANTES ameliorates chronic allograft nephropathy Kidney Int 61 2002 676 685 (Pubitemid 34102611)
96. T. Stojanovic, J. Bedke, H.J. Grone, A.E. Proudfoot, H. Becker, and P. Markus Met-RANTES inhibition of mucosal perfusion failure in acute intestinal transplant rejection - role of endothelial cell-leukocyte interaction J Vasc Res 39 2002 51 58 (Pubitemid 34158359)
97. O. Uchida, N. Kajiwara, A. Hayashi, K. Miyajima, T. Nagatsuka, and H. Hayashi Met-RANTES ameliorates fibrous airway obliteration and decreases ERK expression in a murine model of bronchiolitis obliterans Ann Thorac Cardiovasc Surg 13 2007 82 86
98. C.M. Lloyd, A.W. Minto, M.E. Dorf, A. Proudfoot, T.N. Wells, and D.J. Salant RANTES and monocyte chemoattractant protein-1 (MCP-1) play an important role in the inflammatory phase of crescentic nephritis, but only MCP-1 is involved in crescent formation and interstitial fibrosis J Exp Med 185 1997 1371 1380 (Pubitemid 27172917)
99. Y. Chvatchko, A.E. Proudfoot, R. Buser, P. Juillard, S. Alouani, and M. Kosco-Vilbois Inhibition of airway inflammation by amino-terminally modified RANTES/CC chemokine ligand 5 analogues is not mediated through CCR3 J Immunol 171 2003 5498 5506 (Pubitemid 37432839)
100. J.A. Gonzalo, C.M. Lloyd, D. Wen, J.P. Albar, T.N. Wells, and A. Proudfoot The coordinated action of CC chemokines in the lung orchestrates allergic inflammation and airway hyperresponsiveness J Exp Med 188 1998 157 167 (Pubitemid 28328614)
101. S.C. Robinson, K.A. Scott, J.L. Wilson, R.G. Thompson, A.E. Proudfoot, and F.R. Balkwill A chemokine receptor antagonist inhibits experimental breast tumor growth Cancer Res 63 2003 8360 8365 (Pubitemid 37549490)
102. C.M. Lloyd, M.E. Dorf, A. Proudfoot, D.J. Salant, and J.C. Gutierrez-Ramos Role of MCP-1 and RANTES in inflammation and progression to fibrosis during murine crescentic nephritis J Leukoc Biol 62 1997 676 680 (Pubitemid 27519779)
103. H.J. Anders, M. Frink, Y. Linde, B. Banas, M. Wornle, and C.D. Cohen CC chemokine ligand 5/RANTES chemokine antagonists aggravate glomerulonephritis despite reduction of glomerular leukocyte infiltration J Immunol 170 2003 5658 5666 (Pubitemid 36617858)
104. M.B. Rookmaaker, M.C. Verhaar, H.C. de Boer, R. Goldschmeding, J.A. Joles, and H.A. Koomans Met-RANTES reduces endothelial progenitor cell homing to activated (glomerular) endothelium in vitro and in vivo Am J Physiol Renal Physiol 293 2007 F624 F630
105. P.D. Doodes, Y. Cao, K.M. Hamel, Y. Wang, R.L. Rodeghero, and T. Kobezda CCR5 is involved in resolution of inflammation in proteoglycan-induced arthritis Arthritis Rheum 60 2009 2945 2953
106. Z. Johnson, C.A. Power, C. Weiss, F. Rintelen, H. Ji, and T. Ruckle Chemokine inhibition - why, when, where, which and how? Biochem Soc Trans 32 2004 366 377 (Pubitemid 38582130)
107. M. Matsui, J. Weaver, A.E. Proudfoot, J.R. Wujek, T. Wei, and E. Richer Treatment of experimental autoimmune encephalomyelitis with the chemokine receptor antagonist Met-RANTES J Neuroimmunol 128 2002 16 22 (Pubitemid 34722359)
108. J. Field, A.C. Marshall, P.J. Hertzog, T.N. Wells, F. Alderuccio, and B.H. Toh Chemokine receptor CCR5 is not required for development of experimental autoimmune gastritis Clin Immunol 109 2003 238 247 (Pubitemid 37338631)
109. M. Diedrichs-Mohring, P.J. Nelson, A.E. Proudfoot, S.R. Thurau, and G. Wildner The effect of the CC chemokine receptor antagonist Met-RANTES on experimental autoimmune uveitis and oral tolerance J Neuroimmunol 164 2005 22 30 (Pubitemid 40826759)
110. M.M. Teixeira, T.N. Wells, N.W. Lukacs, A.E. Proudfoot, S.L. Kunkel, and T.J. Williams Chemokine-induced eosinophil recruitment. Evidence of a role for endogenous eotaxin in an in vivo allergy model in mouse skin J Clin Invest 100 1997 1657 1666 (Pubitemid 27431321)
111. M. Canavese, F. Altruda, and L. Silengo Therapeutic efficacy and immunological response of CCL5 antagonists in models of contact skin reaction PLoS One 5 2010 e8725
112. H.J. Grone, C. Weber, K.S. Weber, E.F. Grone, T. Rabelink, and C.M. Klier Met-RANTES reduces vascular and tubular damage during acute renal transplant rejection: blocking monocyte arrest and recruitment FASEB J 13 1999 1371 1383 (Pubitemid 29382505)
113. J. Bedke, T. Stojanovic, H.J. Grone, M. Heuser, L. Scheele, and A.E. Proudfoot Met-RANTES improves acute-rejection-induced microvascular injury in rat small bowel transplantation Transplant Proc 34 2002 1049 (Pubitemid 34556919)
114. J.J. Yun, D. Whiting, M.P. Fischbein, A. Banerji, Y. Irie, and D. Stein Combined blockade of the chemokine receptors CCR1 and CCR5 attenuates chronic rejection Circulation 109 2004 932 937 (Pubitemid 38252748)
115. M.N. Ajuebor, C.M. Hogaboam, S.L. Kunkel, A.E. Proudfoot, and J.L. Wallace The chemokine RANTES is a crucial mediator of the progression from acute to chronic colitis in the rat J Immunol 166 2001 552 558 (Pubitemid 32038476)
116. O. Morteau, I. Castagliuolo, A. Mykoniatis, J. Zacks, M. Wlk, and B. Lu Genetic deficiency in the chemokine receptor CCR1 protects against acute Clostridium difficile toxin A enteritis in mice Gastroenterology 122 2002 725 733 (Pubitemid 34173824)
117. C.A. Bonville, V.K. Lau, J.M. DeLeon, J.L. Gao, A.J. Easton, and H.F. Rosenberg Functional antagonism of chemokine receptor CCR1 reduces mortality in acute pneumovirus infection in vivo J Virol 78 2004 7984 7989 (Pubitemid 38944283)
118. F.J. Culley, A.M. Pennycook, J.S. Tregoning, J.S. Dodd, G. Walzl, and T.N. Wells Role of CCL5 (RANTES) in viral lung disease J Virol 80 2006 8151 8157 (Pubitemid 44182315)
119. L.N. Sorensen, and S.R. Paludan Blocking CC chemokine receptor (CCR) 1 and CCR5 during herpes simplex virus type 2 infection in vivo impairs host defence and perturbs the cytokine response Scand J Immunol 59 2004 321 333 (Pubitemid 38429300)
120. M.C. Vilela, D.S. Mansur, N. Lacerda-Queiroz, D.H. Rodrigues, G.K. Lima, and R.M. Arantes The chemokine CCL5 is essential for leukocyte recruitment in a model of severe Herpes simplex encephalitis Ann N Y Acad Sci 1153 2009 256 263
121. N.R. Veillard, B. Kwak, G. Pelli, F. Mulhaupt, R.W. James, and A.E. Proudfoot Antagonism of RANTES receptors reduces atherosclerotic plaque formation in mice Circ Res 94 2004 253 261 (Pubitemid 38197459)
122. T. Mateo, Y.N. Abu Nabah, M. Abu Taha, M. Mata, M. Cerda-Nicolas, and A.E. Proudfoot Angiotensin II-induced mononuclear leukocyte interactions with arteriolar and venular endothelium are mediated by the release of different CC chemokines J Immunol 176 2006 5577 5586
123. M. Bhatia, A.E. Proudfoot, T.N. Wells, S. Christmas, J.P. Neoptolemos, and J. Slavin Treatment with Met-RANTES reduces lung injury in caerulein-induced pancreatitis Br J Surg 90 2003 698 704 (Pubitemid 36760598)
124. M.N. Ajuebor, Z. Wondimu, C.M. Hogaboam, T. Le, A.E. Proudfoot, and M.G. Swain CCR5 deficiency drives enhanced natural killer cell trafficking to and activation within the liver in murine T cell-mediated hepatitis Am J Pathol 170 2007 1975 1988 (Pubitemid 47339271)
125. M.L. Berres, R.R. Koenen, A. Rueland, M.M. Zaldivar, D. Heinrichs, and H. Sahin Antagonism of the chemokine Ccl5 ameliorates experimental liver fibrosis in mice J Clin Invest 120 2010 4129 4140
126. H. Akyildiz, A. Akcan, E. Sozuer, C. Kucuk, N. Yilmaz, and K. Deniz The preventive effect of Met-RANTES on postoperative intraperitoneal adhesion formation in the rat model Surgery 144 2008 404 409
127. G.A. Medeiros, J.C. Silverio, A.P. Marino, E. Roffe, V. Vieira, and K. Kroll-Palhares Treatment of chronically Trypanosoma cruzi-infected mice with a CCR1/CCR5 antagonist (Met-RANTES) results in amelioration of cardiac tissue damage Microbes Infect 11 2009 264 273
128. A.A. Silva, E. Roffe, H. Santiago, A.P. Marino, K. Kroll-Palhares, and M.M. Teixeira Trypanosoma cruzi-triggered meningoencephalitis is a CCR1/CCR5-independent inflammatory process J Neuroimmunol 184 2007 156 163 (Pubitemid 46389417)
129. A.P. Marino, A. da Silva, P. dos Santos, L.M. Pinto, R.T. Gazzinelli, and M.M. Teixeira Regulated on activation, normal T cell expressed and secreted (RANTES) antagonist (Met-RANTES) controls the early phase of Trypanosoma cruzi-elicited myocarditis Circulation 110 2004 1443 1449 (Pubitemid 39238021)
130. E. Roffe, F. Oliveira, A.L. Souza, V. Pinho, D.G. Souza, and P.R. Souza Role of CCL3/MIP-1alpha and CCL5/RANTES during acute Trypanosoma cruzi infection in rats Microbes Infect 12 2010 669 676
131. C.E. Repeke, S.B. Ferreira Jr., M. Claudino, E.M. Silveira, G.F. de Assis, and M.J. Avila-Campos Evidences of the cooperative role of the chemokines CCL3, CCL4 and CCL5 and its receptors CCR1+ and CCR5+ in RANKL+ cell migration throughout experimental periodontitis in mice Bone 46 2010 1122 1130
132. D.L. Kiss, J. Longden, G.A. Fechner, and V.M. Avery The functional antagonist Met-RANTES: a modified agonist that induces differential CCR5 trafficking Cell Mol Biol Lett 14 2009 537 547
133. J. Longden, E.L. Cooke, and S.J. Hill Effect of CCR5 receptor antagonists on endocytosis of the human CCR5 receptor in CHO-K1 cells Br J Pharmacol 153 2008 1513 1527 (Pubitemid 351481514)
134. M. Wong, S. Uddin, B. Majchrzak, T. Huynh, A.E. Proudfoot, and L.C. Platanias Rantes activates Jak2 and Jak3 to regulate engagement of multiple signaling pathways in T cells J Biol Chem 276 2001 11427 11431 (Pubitemid 38089337)
135. G. Simmons, P.R. Clapham, L. Picard, R.E. Offord, M.M. Rosenkilde, and T.W. Schwartz Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist Science 276 1997 276 279 (Pubitemid 27172690)
136. O.O. Yang, S.L. Swanberg, Z. Lu, M. Dziejman, J. McCoy, and A.D. Luster Enhanced inhibition of human immunodeficiency virus type 1 by Met-stromal-derived factor 1beta correlates with down-modulation of CXCR4 J Virol 73 1999 4582 4589 (Pubitemid 29246716)
137. S. Rusconi, D.P. Merrill, S. La Seta Catamancio, P. Citterio, E. Bulgheroni, and F. Croce In vitro inhibition of HIV-1 by Met-SDF-1beta alone or in combination with antiretroviral drugs Antivir Ther 5 2000 199 204
138. M. Mack, B. Luckow, P.J. Nelson, J. Cihak, G. Simmons, and P.R. Clapham Aminooxypentane-RANTES induces CCR5 internalisation but inhibits recycling: a novel inhibitory mechanism of HIV infectivity J Exp Med 187 1998 1215 1224 (Pubitemid 28189111)
139. U. Panzer, A. Schneider, J. Wilken, D.A. Thompson, S.B. Kent, and R.A. Stahl The chemokine receptor antagonist AOP-RANTES reduces monocyte infiltration in experimental glomerulonephritis Kidney Int 56 1999 2107 2115 (Pubitemid 30004739)
140. M. Oppermann, M. Mack, A.E. Proudfoot, and H. Olbrich Differential effects of CC chemokines on CC chemokine receptor 5 (CCR5) phosphorylation and identification of phosphorylation sites on the CCR5 carboxyl terminus J Biol Chem 274 1999 8875 8885 (Pubitemid 29164688)
141. O. Hartley, and R.E. Offord Engineering chemokines to develop optimized HIV inhibitors Curr Protein Pept Sci 6 2005 207 219 (Pubitemid 40812746)
142. E.J. Whalen, S. Rajagopal, and R.J. Lefkowitz Therapeutic potential of beta-arrestin- and G protein-biased agonists Trends Mol Med 17 2011 126 139
143. J.M. Escola, G. Kuenzi, H. Gaertner, M. Foti, and O. Hartley CC chemokine receptor 5 (CCR5) desensitization: cycling receptors accumulate in the trans-Golgi network J Biol Chem 285 2010 41772 41780
144. J.R. Townson, G.J. Graham, N.R. Landau, B. Rasala, and R.J. Nibbs Aminooxypentane addition to the chemokine macrophage inflammatory protein-1alpha P increases receptor affinities and HIV inhibition J Biol Chem 275 2000 39254 39261 (Pubitemid 32058944)
145. S.M. Brandt, R. Mariani, A.U. Holland, T.J. Hope, and N.R. Landau Association of chemokine-mediated block to HIV entry with coreceptor internalisation J Biol Chem 277 2002 17291 17299 (Pubitemid 34967764)
146. D.E. Mosier, G.R. Picchio, R.J. Gulizia, R. Sabbe, P. Poignard, and L. Picard Highly potent RANTES analogues either prevent CCR5-using human immunodeficiency virus type 1 infection in vivo or rapidly select for CXCR4-using variants J Virol 73 1999 3544 3550 (Pubitemid 29189792)
147. R. Sabbe, G.R. Picchio, C. Pastore, O. Chaloin, O. Hartley, and R. Offord Donor- and ligand-dependent differences in C-C chemokine receptor 5 reexpression J Virol 75 2001 661 671 (Pubitemid 32037270)
148. Z. Toossi, H. Mayanja-Kizza, J. Baseke, P. Peters, M. Wu, and A. Abraha Inhibition of human immunodeficiency virus-1 (HIV-1) by beta-chemokine analogues in mononuclear cells from HIV-1-infected patients with active tuberculosis Clin Exp Immunol 142 2005 327 332 (Pubitemid 41565249)
149. O. Hartley, H. Gaertner, J. Wilken, D. Thompson, R. Fish, and A. Ramos Medicinal chemistry applied to a synthetic protein: development of highly potent HIV entry inhibitors Proc Natl Acad Sci USA 101 2004 16460 16465 (Pubitemid 39557735)
150. C. Pastore, G.R. Picchio, F. Galimi, R. Fish, O. Hartley, and R.E. Offord Two mechanisms for human immunodeficiency virus type 1 inhibition by N-terminal modifications of RANTES Antimicrob Agents Chemother 47 2003 509 517 (Pubitemid 36158074)
151. T. Kawamura, S.E. Bruse, A. Abraha, M. Sugaya, O. Hartley, and R.E. Offord PSC-RANTES blocks R5 human immunodeficiency virus infection of Langerhans cells isolated from individuals with a variety of CCR5 diplotypes J Virol 78 2004 7602 7609 (Pubitemid 38915907)
152. M.M. Lederman, R.S. Veazey, R. Offord, D.E. Mosier, J. Dufour, and M. Mefford Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5 Science 306 2004 485 487 (Pubitemid 39372448)
153. U. Forssmann, I. Hartung, R. Balder, B. Fuchs, S.E. Escher, and N. Spodsberg n-Nonanoyl-CC chemokine ligand 14, a potent CC chemokine ligand 14 analogue that prevents the recruitment of eosinophils in allergic airway inflammation J Immunol 173 2004 3456 3466 (Pubitemid 39142057)
154. J. Manns, S. Rieder, S. Escher, B. Eilers, W.G. Forssmann, and J. Elsner The allergy-associated chemokine receptors CCR3 and CCR5 can be inactivated by the modified chemokine NNY-CCL11 Allergy 62 2007 17 24 (Pubitemid 44902730)
155. S. Gupta, B. Fuchs, S. Schulz-Maronde, A. Heitland, S.E. Escher, and M. Mack Intravascular inactivation of CCR5 by n-Nonanoyl-CC chemokine ligand 14 and inhibition of allergic airway inflammation J Leukoc Biol 83 2008 765 773 (Pubitemid 351966886)
156. A.J. Marozsan, V.S. Torre, M. Johnson, S.C. Ball, J.V. Cross, and D.J. Templeton Mechanisms involved in stimulation of human immunodeficiency virus type 1 replication by aminooxypentane RANTES J Virol 75 2001 8624 8638 (Pubitemid 32768967)
157. V.S. Torre, A.J. Marozsan, J.L. Albright, K.R. Collins, O. Hartley, and R.E. Offord Variable sensitivity of CCR5-tropic human immunodeficiency virus type 1 isolates to inhibition by RANTES analogs J Virol 74 2000 4868 4876 (Pubitemid 30237915)
158. J.K. Lim, W. Lu, O. Hartley, and A.L. DeVico N-terminal proteolytic processing by cathepsin G converts RANTES/CCL5 and related analogs into a truncated 4-68 variant J Leukoc Biol 80 2006 1395 1404 (Pubitemid 44904978)
159. M. Rafei, P.M. Campeau, J.H. Wu, E. Birman, K. Forner, and M.N. Boivin Selective inhibition of CCR2 expressing lymphomyeloid cells in experimental autoimmune encephalomyelitis by a GM-CSF-MCP1 fusokine J Immunol 182 2009 2620 2627
160. E.J. Fernandez, and E. Lolis Structure, function, and inhibition of chemokines Annu Rev Pharmacol Toxicol 42 2002 469 499 (Pubitemid 34160533)
161. H. Gaertner, O. Lebeau, I. Borlat, F. Cerini, B. Dufour, and G. Kuenzi Highly potent HIV inhibition: engineering a key anti-HIV structure from PSC-RANTES into MIP-1 beta/CCL4 Protein Eng Des Sel 21 2008 65 72 (Pubitemid 351301920)
162. M.R. Mayer, T.R. Parody, A. Datta-Mannan, and M.J. Stone Specificity determinants for chemokine recognition identified using eotaxin-MCP-1 chimeras FEBS Lett 571 2004 166 170 (Pubitemid 38992942)
163. C.Z. Dong, S. Kumar, W.T. Choi, N. Madani, S. Tian, and J. An Different stereochemical requirements for CXCR4 binding and signaling functions as revealed by an anti-HIV, d-amino acid-containing SMM-chemokine ligand J Med Chem 48 2005 7923 7924 (Pubitemid 41798424)
164. C. Blanpain, R. Buser, C.A. Power, M. Edgerton, C. Buchanan, and M. Mack A chimeric MIP-1alpha/RANTES protein demonstrates the use of different regions of the RANTES protein to bind and activate its receptors J Leukoc Biol 69 2001 977 985 (Pubitemid 32577901)
165. C.N. Davis, V. Zujovic, and J.K. Harrison Viral macrophage inflammatory protein-II and fractalkine (CX3CL1) chimeras identify molecular determinants of affinity, efficacy, and selectivity at CX3CR1 Mol Pharmacol 66 2004 1431 1439 (Pubitemid 39564770)
166. K. Neote, W. Darbonne, J. Ogez, R. Horuk, and T.J. Schall Identification of a promiscuous inflammatory peptide receptor on the surface of red blood cells J Biol Chem 268 1993 12247 12249 (Pubitemid 23182370)
167. A. Ben-Baruch, L. Xu, P.R. Young, K. Bengali, J.J. Oppenheim, and J.M. Wang Monocyte chemotactic protein-3 (MCP3) interacts with multiple leukocyte receptors. C-C CKR1, a receptor for macrophage inflammatory protein-1 alpha/Rantes, is also a functional receptor for MCP3 J Biol Chem 270 1995 22123 22128
168. H.M. Sarau, J.A. Rush, J.J. Foley, M.E. Brawner, D.B. Schmidt, and J.R. White Characterization of functional chemokine receptors (CCR1 and CCR2) on EoL-3 cells: a model system to examine the role of chemokines in cell function J Pharmacol Exp Ther 283 1997 411 418 (Pubitemid 27438988)
169. C.C. Chou, J.S. Fine, C. Pugliese-Sivo, W. Gonsiorek, L. Davies, and G. Deno Pharmacological characterization of the chemokine receptor, hCCR1 in a stable transfectant and differentiated HL-60 cells: antagonism of hCCR1 activation by MIP-1beta Br J Pharmacol 137 2002 663 675 (Pubitemid 35333092)
170. P. Wang, X. Yang, W. Xu, K. Li, Y. Chu, and S. Xiong Integrating individual functional moieties of CXCL10 and CXCL11 into a novel chimeric chemokine leads to synergistic antitumor effects: a strategy for chemokine-based multi-target-directed cancer therapy Cancer Immunol Immunother 59 2010 1715 1726
171. S. Kumar, W.T. Choi, C.Z. Dong, N. Madani, S. Tian, and D. Liu SMM-chemokines: a class of unnatural synthetic molecules as chemical probes of chemokine receptor biology and leads for therapeutic development Chem Biol 13 2006 69 79 (Pubitemid 43102581)
172. W.T. Choi, S. Tian, C.Z. Dong, S. Kumar, D. Liu, and N. Madani Unique ligand binding sites on CXCR4 probed by a chemical biology approach: implications for the design of selective human immunodeficiency virus type 1 inhibitors J Virol 79 2005 15398 15404 (Pubitemid 43032322)
173. O. Hartley, K. Dorgham, D. Perez-Bercoff, F. Cerini, A. Heimann, and H. Gaertner Human immunodeficiency virus type 1 entry inhibitors selected on living cells from a library of phage chemokines J Virol 77 2003 6637 6644 (Pubitemid 36666857)
174. G.P. Smith Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface Science 228 1985 1315 1317 (Pubitemid 15000355)
175. H. Jin, I. Kagiampakis, P. Li, and P.J. Liwang Structural and functional studies of the potent anti-HIV chemokine variant P2-RANTES Proteins 78 2010 295 308
176. H. Gaertner, F. Cerini, J.M. Escola, G. Kuenzi, A. Melotti, and R. Offord Highly potent, fully recombinant anti-HIV chemokines: reengineering a low-cost microbicide Proc Natl Acad Sci USA 105 2008 17706 17711
177. R.S. Veazey, B. Ling, L.C. Green, E.P. Ribka, J.D. Lifson, and M. Piatak Jr. Topically applied recombinant chemokine analogues fully protect macaques from vaginal simian-human immunodeficiency virus challenge J Infect Dis 199 2009 1525 1527
178. K. Dorgham, A. Ghadiri, P. Hermand, M. Rodero, L. Poupel, and M. Iga An engineered CX3CR1 antagonist endowed with anti-inflammatory activity J Leukoc Biol 86 2009 903 911
179. N. Heveker, M. Montes, L. Germeroth, A. Amara, A. Trautmann, and M. Alizon Dissociation of the signalling and antiviral properties of SDF-1-derived small peptides Curr Biol 8 1998 369 376 (Pubitemid 28173995)
180. Y. Nishiyama, T. Murakami, S. Shikama, K. Kurita, and N. Yamamoto Anti-HIV-1 peptides derived from partial amino acid sequences of CC-chemokine RANTES. Regulated upon activation, normal T-cell expressed and secreted Bioorg Med Chem 10 2002 4113 4117 (Pubitemid 36164712)
181. N. Heveker, M. Tissot, A. Thuret, J. Schneider-Mergener, M. Alizon, and M. Roch Pharmacological properties of peptides derived from stromal cell-derived factor 1: study on human polymorphonuclear cells Mol Pharmacol 59 2001 1418 1425 (Pubitemid 32510106)
182. S.F. Parmley, and G.P. Smith Antibody-selectable filamentous fd phage vectors: affinity purification of target genes Gene 73 1988 305 318 (Pubitemid 19043263)
183. J.K. Scott, and G.P. Smith Searching for peptide ligands with an epitope library Science 249 1990 386 390
184. P. Loetscher, J.H. Gong, B. Dewald, M. Baggiolini, and I. Clark-Lewis N-terminal peptides of stromal cell-derived factor-1 with CXC chemokine receptor 4 agonist and antagonist activities J Biol Chem 273 1998 22279 22283 (Pubitemid 28399785)
185. Y. Nishiyama, T. Murakami, K. Kurita, and N. Yamamoto Synthesis of some peptides corresponding to the active region of RANTES for chemotaxis and evaluation of their anti-human immunodeficiency virus-1 activity Chem Pharm Bull (Tokyo) 45 1997 2125 2128
186. N. Zhou, Z. Luo, J. Luo, J.W. Hall, and Z. Huang A novel peptide antagonist of CXCR4 derived from the N-terminus of viral chemokine vMIP-II Biochemistry 39 2000 3782 3787 (Pubitemid 30183860)
187. Y. Nishiyama, T. Murakami, K. Kurita, and N. Yamamoto Low-molecular-weight anti-HIV-1 peptides from the amino-terminal sequence of RANTES: possible lead compounds for coreceptor-directed anti-HIV-1 agents Bioorg Med Chem Lett 9 1999 1357 1360 (Pubitemid 29232206)
188. E.J. Ramnarine, A.L. Devico, and S.C. Vigil-Cruz Analogues of N-terminal truncated synthetic peptide fragments derived from RANTES inhibit HIV-1 infectivity Bioorg Med Chem Lett 16 2006 93 95 (Pubitemid 41625649)
189. A. Sachpatzidis, B.K. Benton, J.P. Manfredi, H. Wang, A. Hamilton, and H.G. Dohlman Identification of allosteric peptide agonists of CXCR4 J Biol Chem 278 2003 896 907 (Pubitemid 36790764)
190. A. Faber, C. Roderburg, F. Wein, R. Saffrich, A. Seckinger, and K. Horsch The many facets of SDF-1alpha, CXCR4 agonists and antagonists on hematopoietic progenitor cells J Biomed Biotechnol 2007 2007 26065
191. P. Palladino, B. Tizzano, C. Pedone, R. Ragone, F. Rossi, and G. Saviano Structural determinants of unexpected agonist activity in a retro-peptide analogue of the SDF-1alpha N-terminus FEBS Lett 579 2005 5293 5298 (Pubitemid 41395146)
192. J. Luo, Z. Luo, N. Zhou, J.W. Hall, and Z. Huang Attachment of C-terminus of SDF-1 enhances the biological activity of its N-terminal peptide Biochem Biophys Res Commun 264 1999 42 47 (Pubitemid 29500461)
193. C. Tudan, G.E. Willick, S. Chahal, L. Arab, P. Law, and H. Salari C-terminal cyclization of an SDF-1 small peptide analogue dramatically increases receptor affinity and activation of the CXCR4 receptor J Med Chem 45 2002 2024 2031 (Pubitemid 34477716)
194. L.M. Pelus, H. Bian, S. Fukuda, D. Wong, A. Merzouk, and H. Salari The CXCR4 agonist peptide, CTCE-0021, rapidly mobilises polymorphonuclear neutrophils and hematopoietic progenitor cells into peripheral blood and synergizes with granulocyte colony-stimulating factor Exp Hematol 33 2005 295 307 (Pubitemid 40261311)
195. M.P. Crump, E. Elisseeva, J. Gong, I. Clark-Lewis, and B.D. Sykes Structure/function of human herpesvirus-8 MIP-II (1-71) and the antagonist N-terminal segment (1-10) FEBS Lett 489 2001 171 175 (Pubitemid 32126403)
196. N. Zhou, Z. Luo, J. Luo, X. Fan, M. Cayabyab, and M. Hiraoka Exploring the stereochemistry of CXCR4-peptide recognition and inhibiting HIV-1 entry with D-peptides derived from chemokines J Biol Chem 277 2002 17476 17485 (Pubitemid 34967547)
197. T.N. Wells, F. Guye-Coulin, and K.B. Bacon Peptides from the amino-terminus of RANTES cause chemotaxis of human T-lymphocytes Biochem Biophys Res Commun 211 1995 100 105
198. J.M. Burns, B.C. Summers, Y. Wang, A. Melikian, R. Berahovich, and Z. Miao A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development J Exp Med 203 2006 2201 2213 (Pubitemid 44352240)
199. Z. Luo, X. Fan, N. Zhou, M. Hiraoka, J. Luo, and H. Kaji Structure-function study and anti-HIV activity of synthetic peptide analogues derived from viral chemokine vMIP-II Biochemistry 39 2000 13545 13550
200. C. Boshoff, Y. Endo, P.D. Collins, Y. Takeuchi, J.D. Reeves, and V.L. Schweickart Angiogenic and HIV-inhibitory functions of KSHV-encoded chemokines Science 278 1997 290 294 (Pubitemid 27450876)
201. T.N. Kledal, M.M. Rosenkilde, F. Coulin, G. Simmons, A.H. Johnsen, and S. Alouani A broad-spectrum chemokine antagonist encoded by Kaposi's sarcoma-associated herpesvirus Science 277 1997 1656 1659 (Pubitemid 27446226)
202. B. Wu, E.Y. Chien, C.D. Mol, G. Fenalti, W. Liu, and V. Katritch Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists Science 330 2010 1066 1071
203. A. Lapidot, A. Peled, A. Berchanski, B. Pal, O. Kollet, and T. Lapidot NeoR6 inhibits HIV-1-CXCR4 interaction without affecting CXCL12 chemotaxis activity Biochim Biophys Acta 1780 2008 914 920
204. Z. Luo, N. Zhou, J. Luo, J.W. Hall, and Z. Huang The role of positively charged residues in CXCR4 recognition probed with synthetic peptides Biochem Biophys Res Commun 263 1999 691 695 (Pubitemid 29490688)
205. H. Tamamura, M. Sugioka, Y. Odagaki, A. Omagari, Y. Kan, and S. Oishi Conformational study of a highly specific CXCR4 inhibitor, T140, disclosing the close proximity of its intrinsic pharmacophores associated with strong anti-HIV activity Bioorg Med Chem Lett 11 2001 359 362 (Pubitemid 32115846)
206. E.L. Elisseeva, C.M. Slupsky, M.P. Crump, I. Clark-Lewis, and B.D. Sykes NMR studies of active N-terminal peptides of stromal cell-derived factor-1. Structural basis for receptor binding J Biol Chem 275 2000 26799 26805
207. H. Tamamura, K. Hiramatsu, K. Miyamoto, A. Omagari, S. Oishi, and H. Nakashima Synthesis and evaluation of pseudopeptide analogues of a specific CXCR4 inhibitor, T140: the insertion of an (E)-alkene dipeptide isostere into the betaII'-turn moiety Bioorg Med Chem Lett 12 2002 923 928 (Pubitemid 34214976)
208. T. Ferain, H.R. Hoveyda, F. Ooms, D. Schols, J. Bernard, and G. Fraser Agonist-induced internalisation of CCR5 as a mechanism to inhibit HIV replication J Pharmacol Exp Ther 337 3 2011 655 662
209. A. Egorova, A. Kiselev, M. Hakli, M. Ruponen, V. Baranov, and A. Urtti Chemokine-derived peptides as carriers for gene delivery to CXCR4 expressing cells J Gene Med 11 2009 772 781
210. S. Li, S. Huang, and S.B. Peng Overexpression of G protein-coupled receptors in cancer cells: involvement in tumor progression Int J Oncol 27 2005 1329 1339
211. S. Hassan, M. Buchanan, K. Jahan, A. Aguilar-Mahecha, L. Gaboury, and W.J. Muller CXCR4 peptide antagonist inhibits primary breast tumor growth, metastasis and enhances the efficacy of anti-VEGF treatment or docetaxel in a transgenic mouse model Int J Cancer 129 2011 225 232
212. S.Y. Kim, C.H. Lee, B.V. Midura, C. Yeung, A. Mendoza, and S.H. Hong Inhibition of the CXCR4/CXCL12 chemokine pathway reduces the development of murine pulmonary metastases Clin Exp Metastasis 25 2008 201 211
213. S. Porvasnik, N. Sakamoto, S. Kusmartsev, E. Eruslanov, W.J. Kim, and W. Cao Effects of CXCR4 antagonist CTCE-9908 on prostate tumor growth Prostate 69 2009 1460 1469
214. + cells in synergy with other cytokines and enhances their ex vivo expansion and engraftment into nonobese diabetic/severe combined immunodeficient mice Stem Cells 24 2006 55 64
215. B. Singh, K.R. Cook, C. Martin, E.H. Huang, K. Mosalpuria, and S. Krishnamurthy Evaluation of a CXCR4 antagonist in a xenograft mouse model of inflammatory breast cancer Clin Exp Metastasis 27 2010 233 240
216. D. Wong, and W. Korz Translating an antagonist of chemokine receptor CXCR4: from bench to bedside Clin Cancer Res 14 2008 7975 7980
217. R. Zhong, P. Law, D. Wong, A. Merzouk, H. Salari, and E.D. Ball Small peptide analogs to stromal derived factor-1 enhance chemotactic migration of human and mouse hematopoietic cells Exp Hematol 32 2004 470 475 (Pubitemid 38624331)
218. J. Wilken, D. Hoover, D.A. Thompson, P.N. Barlow, H. McSparron, and L. Picard Total chemical synthesis and high-resolution crystal structure of the potent anti-HIV protein AOP-RANTES Chem Biol 6 1999 43 51 (Pubitemid 29363044)